
Photo: LVM3 launch, Sriharikota, ISRO, GODL-India
APPSC Group-I Mains 2020 · Paper V
2020 Paper V · Q15(b): model answer
Science, Technology & Environmental Issues · Biotechnology and health. Held in December 2020 (Notification 27/2018).
The 2020 Nobel Prize for Physiology and Medicine was awarded to three scientists for their work on HCV. What do you know about this virus and the disease it causes? Is there any vaccine available for this disease?
Syllabus: Biotechnology and health · Health and diseases
Hepatitis C virusChronic liver diseaseDirect-acting antiviralsNo vaccine
The 2020 Nobel Prize in Physiology or Medicine went to Harvey J. Alter, Michael Houghton and Charles M. Rice "for the discovery of Hepatitis C virus". Their work explained the mysterious "non-A, non-B" hepatitis that followed blood transfusions, made blood screening possible and led to drugs that now cure the infection. Yet hepatitis C still affects about 47 million people worldwide (WHO, 2026).
1. The Nobel-winning discovery
- Harvey Alter (US National Institutes of Health, 1970s) showed that unexplained transfusion hepatitis was caused by an unknown virus that could be passed to chimpanzees.
- Michael Houghton (Chiron, 1989) isolated the virus's genetic sequence, and it was named the hepatitis C virus (HCV).
- Charles Rice (1997) proved that HCV alone causes hepatitis, by injecting its engineered genetic material into a chimpanzee.
2. The virus and the disease
- Virus: a small, enveloped, single-stranded RNA virus of the flavivirus family (genus Hepacivirus); error-prone copying creates many genotypes and fast-changing variants within each patient.
- Spread through blood: unsafe injections and medical procedures, unscreened transfusions and shared needles among people who inject drugs; less often from mother to baby or through sex. It does not spread through food, water, breast milk or casual contact.
- A "silent" disease: most new infections cause no symptoms. About 30% of people clear the virus within six months; the rest develop chronic infection, and 15–30% of them get cirrhosis within 20 years, which can lead to liver failure and liver cancer.
- Burden (WHO, 2026): about 0.9 million new infections a year and about 239,000 deaths in 2024; only about a third of infected people know their status.
- Diagnosis and cure: an antibody test is followed by an HCV RNA test to confirm infection. Oral direct-acting antivirals (DAAs), such as sofosbuvir with daclatasvir or velpatasvir, cure more than 95% of patients in 12–24 weeks. India's National Viral Hepatitis Control Programme (2018) provides free testing and DAA treatment with low-cost Indian generics.
3. Is there a vaccine?
No. As of 2026, WHO states that there is no effective vaccine against hepatitis C, unlike hepatitis A and B.
- Why it is hard: HCV has many genotypes and mutates quickly, hiding its envelope proteins from antibodies; natural infection does not give lasting protection, so people can be re-infected; and good animal models are lacking.
- Trials so far: a viral-vector vaccine tested in the USA did not prevent chronic infection (2021); research continues.
- Prevention today: safe injections (auto-disable syringes), screening of all donated blood, harm reduction for people who inject drugs, and "test and treat", since cure also stops further spread.
| Virus | Main spread | Chronic infection | Vaccine |
|---|---|---|---|
| Hepatitis A | Contaminated food and water | No | Yes |
| Hepatitis B | Blood, sex, mother to child | Yes, mostly if infected as a baby | Yes; birth dose in the UIP |
| Hepatitis C | Blood | Yes, in most | No; curable with DAAs |
| Hepatitis E | Contaminated water | Rarely | One licensed in China; not in India's programme |
HCV went from discovery to cure in three decades; without a vaccine, WHO's goal of eliminating hepatitis C as a public-health threat by 2030 depends on screening, cheap DAAs and safe injections.
The other choice in Q15
Answer either one in the exam.
Every model answer on these pages is free to read. The Tool Kit adds four PDF books for Mains Papers I–IV: every previous question sorted by syllabus, with practice questions. It is in the ₹149 All-in-One Pass, with every previous paper of every exam on the site, practice quizzes, timed tests, mock test series and study books.
₹149 · valid for 12 months from the day you pay, on every exam · pay by UPI, card or net banking